[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns].
OBJECTIVE
For the therapy of preeclamptic patients is Urapidil besides Dihydralazine another possible option for iv-therapy with good results in first clinical studies. Effects of both drugs on the newborns were observed. -


METHODS
The maternal and fetal Urapidil plasma-concentrations and cardiovascular parameters of the newborns were observed in a randomised comparative therapy-study. -


RESULTS
We found low fetal Urapidil plasma-concentrations as well as a less influence on cardiovascular parameters compared to dihydralazine. -


CONCLUSIONS
With Urapaidil we have another therapeutic option in preeclampsia where we could not show any negative side-effects on the newborns.
Schulz
M
M
Universitäts-Frauenklinik, Heidelberg. michael_schulz@med.uni-heidelberg.de
Wacker
J
J
Bastert
G
G
D000328:Adult; D000959:Antihypertensive Agents / Q000097:blood / Q000627:therapeutic use*; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D004078:Dihydralazine / Q000097:blood / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn / Q000097:blood*; D008431:Maternal-Fetal Exchange; D010879:Piperazines / Q000097:blood / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D010879:Piperazines; C015568:urapidil; D004078:Dihydralazine